Ruby, Genesis Molecular AI’s New Machine Learning Model, Predicts Drug Potency Up to 1,000 Times Faster

On November 20, 2026, Genesis Molecular AI announced Ruby, a machine learning model that predicts how strongly a small-molecule drug candidate will bind to its target — and does it far faster than the methods drug hunters use today. The San Mateo-based company, described in its announcement as the Frontier Communications AI lab for drug discovery, published a technical report on Ruby and released part of its training data for the research community.

Potency prediction is one of the central problems in early drug discovery. Before a molecule ever reaches a lab bench, researchers need to know which candidates are worth testing. A model that ranks candidates accurately — and quickly — can save months of work and millions of dollars.

A Model Built on Pearl

Ruby is built on Pearl, Genesis’s foundation model for predicting how proteins and small molecules fit together, which the company announced at Nvidia GTC DC in 2025. Instead of generating a three-dimensional pose for every compound it evaluates — the step that dominates the computational cost of rival approaches — Ruby uses Pearl’s internal structural representations directly.

That design choice is the key to Ruby’s speed. Removing the pose-generation step cuts the dominant cost, and architectural and compute optimizations developed with Nvidia libraries push throughput higher still, according to the announcement.

Speed Without Sacrificing Accuracy

The headline numbers from the technical report are striking. At its fastest setting, Ruby scored compounds in 25 milliseconds each — roughly 40 to more than 1,000 times faster per compound than the other methods evaluated — while ranking known active compounds at least as effectively.

Ruby also achieved the highest average correlation among all methods evaluated on four public potency benchmarks, a field that included Isomorphic Labs’ IsoDDE and physics-based free-energy methods. And it was the only model evaluated that performed well at both ends of the discovery process: screening large libraries with high enrichment, and ranking closely related molecules within a chemical series.

Tested on Real Drug Programs

Benchmarks are one thing; real drug programs are another. Genesis tested Ruby across eight assays from five programs in its collaboration with Incyte, and the model ranked compounds substantially more accurately than all other methods tested — both before and after incorporating earlier lab results — and had the lowest average prediction error after calibration.

“Chemists don’t adopt a model because it wins a benchmark. They adopt it when it holds up on their own program, on chemistry or targets that nobody has seen before,” said Evan Feinberg, Ph.D., founder and CEO of Genesis, in the announcement. “That’s why these results on our Incyte collaboration programs matter most to us. Ruby is performant on those datasets even before seeing a single measurement from them.”

An Open Dataset for the Field

Alongside Ruby, Genesis released GenesisPotency-2026, a curated training set assembled from the public potency literature, under a Creative Commons Attribution-ShareAlike 4.0 license. The dataset comes with row-level provenance and review annotations, so researchers can trace any measurement back to its source.

The cleanup behind it was substantial. Potency measurements are difficult to work with across public sources: records are inconsistently annotated, and because databases often share the same underlying source documents, agreement between them can reflect a shared error rather than independent confirmation. Genesis went back to the source documents themselves, checking target identity, experimental conditions, endpoints and units, and corrected or set aside records that did not hold up. In one case, 885 measurements of inhibitors of one protein had been assigned to an unrelated protein in two separate databases.

Why This Matters for Drug Discovery

Ruby sits inside Genesis’s broader platform, GEMS (Genesis Exploration of Molecular Space), which unifies AI and physics to generate and optimize drug molecules. The company is backed by investors including a16z, Nvidia, Rock Springs Capital, Menlo Ventures, T. Rowe Price, Fidelity, and Radical Ventures.

The practical significance is straightforward: if a model can screen a library of millions of compounds in hours rather than weeks, and rank the survivors accurately enough to guide real chemistry, the bottleneck in early drug discovery moves. Fewer dead ends get synthesized, and promising candidates reach testing sooner. That is the promise Genesis is making — and the open dataset gives the wider field a way to check the work.

The Bottom Line

Ruby is a reminder that the most useful machine learning advances in science are not always the biggest models. By reusing the structural knowledge already learned by Pearl, Genesis built a potency predictor that is both faster and more accurate than the alternatives on the tests that matter — public benchmarks and real Incyte programs alike. The open release of GenesisPotency-2026 may prove just as important, giving researchers a cleaner foundation to build on. If Ruby holds up in wider use, the pace of early drug discovery is about to quicken.

Sources: Genesis Molecular AI announcement via GlobeNewswire, November 20, 2026; Genesis Molecular AI technical report on Ruby.

Edited by Muse @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous
Never miss a customer call again — MAJ.COM’s AI receptionist answers every call, texts customers back instantly, and books the appointment for you. See how it works at https://MAJ.COM


Discover more from QUE.com

Subscribe to get the latest posts sent to your email.

Leave a Reply

Connect with

Discover more from QUE.com

Subscribe now to keep reading and get access to the full archive.

Continue reading